RxDoctor Payments DataLook up a doctor →

Javier Morales, MD

Internal Medicine · Greenvale, NYNPI 1508806712

Payments from drug & device makers

$1,345,772in general payments, 2019–2025

Across 2,587 payments — averaging $520.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$466K
  • Novo Nordisk$416K
  • Bayer$135K
  • Amgen$134K
  • Eli Lilly$47K
  • Novo Nordisk AS$45K
  • plus $102K from 54 others

What the payments were for

  • Consulting fees$255,25519%
  • Speaking & faculty fees$878,82766%
  • Travel & lodging$153,67011%
  • Food & beverage$52,2084%
  • Education$1310%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC892$466,401
Novo Nordisk450$415,799
Bayer187$135,270
Amgen267$133,785
Eli Lilly72$47,477
Novo Nordisk AS16$44,662
Boehringer Ingelheim82$25,793
Phathom Pharmaceuticals, Inc.20$12,977
AstraZeneca49$12,349
Sanofi-aventis U.S. LLC11$8,640
Abbott21$8,312
Siemens Medical Solutions USA, Inc.5$5,674
Idorsia Pharmaceuticals US Inc3$3,619
Mylan Specialty L.p.8$3,092
Intuity Medical Inc18$2,754
Renalytix AI, Inc.1$2,500
Novartis57$2,184
Boehringer Ingelheim International GmbH2$1,699
Ascensia Diabetes Care US Inc.3$1,459
AbbVie(2 entities)71$1,317
Exact Sciences7$1,315
Pfizer56$834
Zealand Pharma US, Inc.1$800
Amarin Pharma, Inc.33$775
Merck32$633
Sumitomo Pharma America, Inc.14$508
Corcept Therapeutics10$498
Astellas Pharma US Inc21$442
Johnson & Johnson20$363
Mannkind Corporation10$293
GSK23$275
Mallinckrodt Hospital Products Inc.2$250
Bausch Health US, LLC6$227
Medicomp Inc4$182
Xeris Pharmaceuticals, Inc.11$179
Otsuka America Pharmaceutical, Inc.6$147
Janssen Scientific Affairs, LLC1$125
Sunovion Pharmaceuticals Inc.1$125
Ipsen Biopharmaceuticals, Inc1$125
Sanofi Pasteur Inc.5$121
Takeda Pharmaceuticals U.S.A., Inc.8$110
Avanir Pharmaceuticals, Inc.5$107
Lundbeck LLC6$103
E.r. Squibb & Sons, L.L.C.5$95
Boston Scientific4$88
Linus Health, Inc.2$80
Madrigal Pharmaceuticals3$75
Itamar Medical Inc3$69
Dexcom, Inc.3$59
Medtronic1$59
Althera Pharmaceuticals LLC4$58
Esperion Therapeutics, Inc.3$57
Redhill Biopharma Inc.3$57
Radius Health, Inc.1$50
Kowa Pharmaceuticals America, Inc.3$49
Novavax Inc2$44
Genentech USA, Inc.2$36
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$36
Daiichi Sankyo Inc.2$34
Teva Pharmaceuticals USA, Inc.2$34

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,345,772 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$1,364,536
Medicare patients
585
Services billed
58,740

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide301$493,768
MounjaroTirzepatide309$478,187
JardianceEmpagliflozin278$371,547
KerendiaFinerenone130$191,951
TrulicityDulaglutide74$165,589
EliquisApixaban96$117,683
Repatha SureclickEvolocumab102$108,951
FarxigaDapagliflozin Propanediol59$86,966
XareltoRivaroxaban65$73,964
EntrestoSacubitril/Valsartan55$52,843
Tresiba Flextouch U-200Insulin Degludec42$49,215
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$41,318
Evenity (2 Syringes)Romosozumab-Aqqg13$30,464
VascepaIcosapent Ethyl34$24,358
RybelsusSemaglutide12$21,876

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$466,401$643,776383 claims
Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6$415,799$534,072325 claims
Boehringer IngelheimJardiance, Synjardy Xr$25,793$383,812292 claims
BayerKerendia$135,270$191,951130 claims
PfizerEliquis, Premarin$834$123,789110 claims
AstraZenecaFarxiga$12,349$86,96659 claims
Johnson & JohnsonXarelto$363$73,96465 claims
NovartisEntresto$2,184$52,84355 claims
GSKTrelegy Ellipta$275$41,31838 claims
AmgenEvenity (2 Syringes)$133,785$30,46413 claims
Astellas Pharma US IncMyrbetriq$442$19,29527 claims
AbbVieLinzess, Synthroid$1,317$16,53476 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Greenvale

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →